Compare Halliburton Company (HAL) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Halliburton Company vs Mesoblast Limited — how do they compare? Halliburton Company trades at $32.44 (market cap $26.45B), while Mesoblast Limited trades at $13.8 (market cap $1.81B). The key difference: Halliburton Company is far larger — about 14.6× Mesoblast Limited's market cap, and Halliburton Company pays a 2.14% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals — on Pluang, investors hold Halliburton Company for 89 Days and Mesoblast Limited for 14 Days on average.
| HAL | MESO | |
|---|---|---|
Market Cap | $26.45B | $1.81B |
Volume | 11,229,274 | 240,620 |
Sector | Energy | Health |
52-Week High | $42.98 | $20.96 |
52-Week Low | $21.82 | $13.19 |
Typical Hold Time | 89 Days | 14 Days |
Enterprise Value | $32.60B | $1.89B |
Dividend Yield | 2.14% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Halliburton (HAL) trades at $31.75, down 2.96% on the day, with technical indicators showing bearish momentum. The stock has demonstrated consistent earnings beats in recent quarters and maintains solid profitability metrics including 7.16% net margin and 14.89% ROE. Recent developments include expansion into Venezuela through partnerships with Eneva and WESCA, along with a major contract win for Cyprus' Cronos gas project, positioning the company for international growth opportunities.
Despite near-term technical weakness, Halliburton presents value with a 16.62 P/E ratio and strong analyst support (73% buy ratings) targeting $43.11 consensus. Risks include oil price volatility and execution challenges in new international markets, but the company's diversified service portfolio and improving cash flow trends support long-term growth prospects in the energy services sector.
MESO trades at $13.94, up 2.42% on the day, amid a bearish technical signal from moving averages. The company reported a significant revenue increase to $120 million in 2026, up from $17 million in 2025, but remains unprofitable with a net loss of $58 million. Recent milestones include FDA approval for a new potency assay for Ryoncil and completion of a Phase 3 trial for chronic back pain treatment, positioning it for potential future growth.
The outlook is cautiously optimistic due to strong revenue growth and key regulatory progress, yet high cash burn and persistent losses present substantial risks. Analyst sentiment is mixed, with a 45% buy rating, but the stock faces headwinds from its negative profit margins and competitive pressures in the biotech sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Halliburton Company
Halliburton is one of the three largest oilfield service firms in the world, offering superior expertise in a number of business lines, including completion fluids, wireline services, cementing, and countless others. It's the number one pressure pumper in North America, and has been a leading innovator in hydraulic fracturing over the last two decades.
Read more on HAL →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
